Migraine in the triptan era: Lessons from epidemiology, pathophysiology, and clinical science

Headache

Volumn 49, Issue SUPPL. 1, 2009, Pages

  Bigal, Marcelo E ^a,g   Ferrari, Michel ^b   Silberstein, Stephen D ^c   Lipton, Richard B ^d,e   Goadsby, Peter J ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JEFFERSON HEADACHE CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE   (United States)

Author keywords

Migraine epidemiology; Pathophysiology; Triptans

Indexed keywords

NEUROTRANSMITTER; OLCEGEPANT; PENTIAPINE; TRIPTAN DERIVATIVE;

ALLODYNIA; CLINICAL PRACTICE; COMORBIDITY; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FAMILIAL HEMIPLEGIC MIGRAINE; FATIGUE; GENETIC ASSOCIATION; HEADACHE; HEREDITY; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MIGRAINE; MIGRAINE WITH AURA; NEUROIMAGING; NEUROTRANSMITTER RELEASE; OBESITY; PATHOPHYSIOLOGY; PHONOPHOBIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SPREADING CORTICAL DEPRESSION; SYMPTOM; TENSION HEADACHE; TRIGEMINAL NERVE; YAWNING;

CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 58649102662     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01336.x     Document Type: Review

References (92)

1. Lance JW, Goadsby PJ. Mechanism and Management of Headache, 7th edn. New York : Elsevier 2005.
2. Woakes E. On ergot of rye in the treatment of neuralgia. Br Med J. 1868 2 : 360 361.
3. Wolff HG. Headache and Other Head Pain, 1st edn. New York : Oxford University Press 1948.
4. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci. 1990 600 : 587 598.
5. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002 346 : 257 270.
6. Humphrey PPA, Goadsby PJ. Controversies in headache. The mode of action of sumatriptan is vascular? A debate. Cephalalgia. 1994 14 : 401 410.
7. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001 41 : 638 645.
8. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
9. Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD. The prevalence of premonitory symptoms in migraine: A questionnaire study in 461 patients. Cephalalgia. 2006 26 : 1209 1213.
10. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. Neurology. 2003 60 : 935 940.
11. Waelkens J. Domperidone in the prevention of complete classical migraine. Br Med J. 1981 284 : 944.
12. Waelkens J. Dopamine blockade with domperidone: Bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984 4 : 85 90.
13. Bartsch T, Goadsby PJ. Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. Headache Currents. 2005 2 : 42 48.
14. Obermann M, Yoon M-S, Dommes P, et al. Prevalence of trigeminal autonomic symptoms in migraine: A population-based study. Cephalalgia. 2007 27 : 504 509.
15. May A, Goadsby PJ. The trigeminovascular system in humans: Pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999 19 : 115 127.
16. Frese A, Evers S, May A. Autonomic activation in experimental trigeminal pain. Cephalalgia. 2003 23 : 67 68.
17. May A, Buchel C, Turner R, Goadsby PJ. MR-angiography in facial and other pain: Neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab. 2001 21 : 1171 1176.
18. Knight YE, Classey JD, Lasalandra MP, et al. Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res. 2005 1045 : 1 11.
19. Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. Neurology. 2001 56 : 436 441.
20. Brandt T, Strupp M. Migraine and vertigo: Classification, clinical features, and special treatment considerations. Headache Currents. 2006 3 : 12 19.
21. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: Relation to age, income, race and other sociodemographic factors. JAMA. 1992 267 : 64 69.
22. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 41 : 646 657.
23. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine and chronic migraine. Possible mechanisms of interaction. Neurology. 2007 68 : 1851 1861.
24. Diener HC, Kurth T, Dodick D. Patent foramen ovale and migraine. Curr Pain Headache Rep. 2007 11 : 236 240.
25. Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention with STARFlex Technology (MIST) Trial. A Prospective, Multicenter, Double-Blind, Sham-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With STARFlex Septal Repair Implant to Resolve Refractory Migraine Headache. Circulation. 2008 117 : 1397 1404.
26. Ambrosini A, de Noordhout AM, Sandor PS, Schoenen J. Electrophysiological studies in migraine: A comprehensive review of their interest and limitations. Cephalalgia. 2003 23 (Suppl. 1 13 31.
27. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SMA, Picavet HSJ, Launer LJ. The impact of migraine on quality of life in the general population. The GEM Study. Neurology. 2000 55 : 624 629.
28. Lipton RB, Hemelsky SW, Kolodner KN, Steiner TJ, Stewart WF. Migraine, quality of life and depression. A population-based case-control study. Neurology. 2000 55 : 629 635.
29. Di Clemente L, Coppola G, Magis D, et al. Interictal habituation deficit of the nociceptive blink reflex: An endophenotypic marker for presymptomatic migraine? Brain. 2007 130 : 765 770.
30. Coppola G, Vandenheede M, Di Clemente L, et al. Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. Brain. 2005 128 : 98 103.
31. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004 291 : 427 434.
32. Rozen TD. Vanishing cerebellar infarcts in a migraine patient. Cephalalgia. 2007 27 : 557 560.
33. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003 106 : 81 89.
34. Katsarava Z, Limmroth V, Finke M, Diener H-C, Fritsche G. Rates and predictors for relapse in medication overuse headache: A 1-year prospective study. Neurology. 2003 60 : 1682 1683.
35. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 41 : 303 309.
36. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? Headache. 2003 43 : 179 190.
37. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in cluster headache patients. Neurology. 2006 67 : 109 113.
38. Goadsby PJ. Is medication-overuse headache a distinct biological entity? Nat Clin Pract Neurol. 2006 2 : 401.
39. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: A prospective study. Neurology. 2005 64 : 1020 1026.
40. Ferrari MD. Migraine. Lancet. 1998 351 : 1043 1051.
41. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. Evidence of a genetic factor in migraine with aura: A population based Danish twin study. Ann Neurol. 1999 45 : 242 246.
42. Russell MB, Ulrich V, Gervil M, Olesen J. Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. Headache. 2002 42 : 332 336.
43. 2+ channel gene CACNL1A4. Cell. 1996 87 : 543 552.
44. van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004 41 : 701 710.
45. + pump α2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003 33 : 192 196.
46. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A causes familial hemiplegic migraine. Lancet. 2005 366 : 371 377.
47. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994 117 : 199 210.
48. Haerter K, Ayata C, Moskowitz MA. Cortical spreading depression: A model for understanding migraine biology and future drug targets. Headache Currents. 2005 2 : 97 103.
49. Goadsby PJ. Migraine, aura and cortical spreading depression: Why are we still talking about it? Ann Neurol. 2001 49 : 4 6.
50. Goadsby PJ, Oshinsky M. The pathophysiology of migraine. In : Silberstein SD, Lipton RB, Dodick D, eds. Wolff's Headache and Other Head Pain, 8th edn. New York : Oxford 2008 : 105 119.
51. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002 8 : 136 142.
52. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 1 : 658 660.
53. Afridi S, Giffin NJ, Kaube H, et al. A PET study in spontaneous migraine. Arch Neurol. 2005 62 : 1270 1275.
54. Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner RL, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain. 2004 127 : 220 230.
55. Afridi S, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005 128 : 932 939.
56. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001 357 : 1016 1017.
57. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987 27 : 416 420.
58. Veloso F, Kumar K, Toth C. Headache secondary to deep brain implantation. Headache. 1998 38 : 507 515.
59. Haas DC, Kent PF, Friedman DI. Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache. 1993 33 : 452 455.
60. Goadsby PJ. Neurovascular headache and a midbrain vascular malformation - evidence for a role of the brainstem in chronic migraine. Cephalalgia. 2002 22 : 107 111.
61. Afridi S, Goadsby PJ. New onset migraine with a brainstem cavernous angioma. J Neurol Neurosurg Psychiat. 2003 74 : 680 682.
62. Obermann M, Gizewski ER, Limmroth V, Diener H-C, Katsarava Z. Symptomatic migraine and pontine vascular malformation: Evidence for a key role of the brainstem in the pathophysiology of chronic migraine. Cephalalgia. 2006 26 : 763 766.
63. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol. 1988 23 : 193 196.
64. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 28 : 183 187.
65. Goadsby PJ. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005 65 : 2557 2567.
66. Peroutka SJ. Neurogenic inflammation and migraine: Implications for therapeutics. Mol Interv. 2005 5 : 306 313.
67. Olesen J, Diener H-C, Husstedt I-W, et al. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med. 2004 350 : 1104 1110.
68. Ho T, Mannix L, Fan X, et al. Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 70 : 1004 1012.
69. Goadsby PJ. Calcitonin gene-related peptide (CGRP) antagonists and migraine - is this a new era? Neurology. 2008 70 : 1300 1301.
70. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia. 1988 8 : 83 91.
71. May A, Shepheard S, Wessing A, Hargreaves RJ, Goadsby PJ, Diener HC. Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain. 1998 121 : 1231 1237.
72. Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: A population study. Neurology. 2008 70 : 1525 1533.
73. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996 384 : 560 563.
74. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitisation. Ann Neurol. 2004 55 : 27 36.
75. Knight YE, Goadsby PJ. The periaqueductal gray matter modulates trigeminovascular input: A role in migraine? Neuroscience. 2001 106 : 793 800.
76. Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: A functional genetic link for migraine? J Neurosci. 2002 22 : 1 6.
77. 1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann Neurol. 2004 56 : 371 381.
78. Holland PR, Akerman S, Goadsby PJ. The orexins and their involvement in the modulation of trigeminovascular nociceptive transmission. Cephalalgia. 2006 26 : 1363.
79. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] Orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004 109 : 367 378.
80. Dahlstrom A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand. 1964 62 (Suppl. 232 1 55.
81. Charbit AR, Holland PR, Goadsby PJ. Stimulation or lesioning of dopaminergic A11 cell group affects neuronal firing in the trigeminal nucleus caudalis. Cephalalgia. 2007 27 : 605.
82. Bergerot A, Storer RJ, Goadsby PJ. Dopamine inhibits trigeminovascular transmission in the rat. Ann Neurol. 2007 61 : 251 262.
83. Blin O, Azulay J, Masson G, Aubrespey G, Serratrice G. Apomorphine-induced yawning in migraine patients: Enhanced responsiveness. Clin Neuropharmacol. 1991 14 : 91 95.
84. Peroutka SJ. Dopamine and migraine. Neurology. 1997 49 : 650 656.
85. Afridi SK, Goadsby PJ. Neuroimaging of migraine. Curr Pain Headache Rep. 2006 10 : 221 224.
86. Welch KM, Nagesh V, Aurora S, Gelman N. Periaqueductal grey matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001 41 : 629 637.
87. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004 113 : 1447 1455.
88. Granziera C, DaSilva AFM, Snyder J, Tuch DS, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med. 2006 3 : e402.
89. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006 59 : 652 661.
90. Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol. 2005 18 : 305 310.
91. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006 46 : 1334 1343.
92. Bigal ME, Lipton RB. Cinical course in migraine: Conceptualizing migraine transformation. Neurology. 2008 71 : 848 855.